Product Code: GVR-4-68039-044-2
Bacterial And Viral Specimen Collection Market Growth & Trends:
The global bacterial and viral specimen collection market size is anticipated to reach USD 33.37 billion by 2030 and expand at a CAGR of 14.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing burden of infectious diseases such as COVID-19, influenza, and tuberculosis has significantly increased the demand for bacterial and viral specimen collection. As healthcare systems strive to contain outbreaks and improve patient outcomes, governments and private sectors are ramping up healthcare investments. This surge in healthcare spending supports expanded diagnostic testing, better infrastructure, and the development of efficient specimen collection tools, ultimately driving market growth.
Technological advancements in diagnostics, including PCR, molecular assays, and rapid test platforms, have revolutionized the way infections are detected. These innovations require reliable and high-quality specimen collection methods to ensure accuracy. In addition, rising awareness among healthcare providers and patients about the importance of early and precise diagnosis increases testing volumes, thereby fueling demand for advanced specimen collection tools and boosting the overall market size.
The shift toward decentralized healthcare, driven by the convenience and accessibility of home testing and point-of-care diagnostics, is reshaping the specimen collection landscape. These trends reduce reliance on traditional lab settings and increase sample collection frequency. In addition, expanding research and clinical trials for vaccines, therapeutics, and infectious disease surveillance are boosting demand for standardized specimen collection kits, contributing significantly to the market's growth and broadening its application across various sectors.
Bacterial And Viral Specimen Collection Market Report Highlights:
- By product, the viral specimen collection segment led the market with the largest revenue share of 57.3% in 2024, attributed to the rising prevalence of viral infections, including influenza, hepatitis, and emerging viral outbreaks.
- By application, the diagnostics segment dominated the market with the largest share in 2024, driven by the growing demand for accurate and early disease detection.
- The research segment is projected to witness significant growth from 2025 to 2030 due to technological advancements in diagnostic tools, such as next-generation sequencing and multiplex PCR, which enhance the accuracy and efficiency of specimen analysis.
- The home testing segment is anticipated to be the fastest-growing segment during the forecast period, fueled by increasing consumer demand for convenient, private, and accessible diagnostic solutions.
- North America accounted for the largest revenue share of 45% in 2024, propelled by the high prevalence of infectious diseases, substantial healthcare investments, advanced infrastructure, and robust research and development initiatives.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and Forecasts Timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.5. Details of Primary Research
- 1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product Outlook
- 2.2.2. Application Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
- 2.3. Competitive Scenario
Chapter 3. Bacterial and Viral Specimen Collection Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Bacterial and Viral Specimen Collection Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political Landscape
- 3.3.2.2. Technological Landscape
- 3.3.2.3. Economic Landscape
Chapter 4. Bacterial and Viral Specimen Collection Market: Product Estimates & Trend Analysis
- 4.1. Product Segment Dashboard
- 4.2. Bacterial and Viral Specimen Collection Market: Product Movement Analysis
- 4.3. Global Bacterial and Viral Specimen Collection Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
- 4.4. Bacterial Specimen Collection
- 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.2. Swabs
- 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.3. Bacterial Transport Media
- 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.4. Blood Collection Kits
- 4.4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.4.5. Other Consumables
- 4.4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5. Viral Specimen Collection
- 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.2. Swabs
- 4.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.3. Viral Transport Media
- 4.5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.4. Blood Collection Kits
- 4.5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5.5. Other Consumables
- 4.5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Bacterial and Viral Specimen Collection Market: Application Estimates & Trend Analysis
- 5.1. Application Segment Dashboard
- 5.2. Bacterial and Viral Specimen Collection Market: Application Movement Analysis
- 5.3. Global Bacterial and Viral Specimen Collection Market Size & Trend Analysis, By Application, 2018 to 2030 (USD Million)
- 5.4. Diagnostics
- 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 5.5. Research
- 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Bacterial and Viral Specimen Collection Market: End Use Estimates & Trend Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Bacterial and Viral Specimen Collection Market: End Use Movement Analysis
- 6.3. Global Bacterial and Viral Specimen Collection Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
- 6.4. Hospitals & Clinics
- 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 6.5. Home Testing
- 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 6.6. Research Laboratories
- 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Bacterial and Viral Specimen Collection Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Dashboard
- 7.2. Regional Market Share Analysis, 2024 & 2030
- 7.3. Bacterial and Viral Specimen Collection Market by Region: Key Takeaways
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key Country Dynamics
- 7.4.1.2. Regulatory Framework/ Reimbursement Structure
- 7.4.1.3. Competitive Scenario
- 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory Framework/ Reimbursement Structure
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory Framework/ Reimbursement Structure
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5. Europe
- 7.5.1. U.K.
- 7.5.1.1. Key Country Dynamics
- 7.5.1.2. Regulatory Framework/ Reimbursement Structure
- 7.5.1.3. Competitive Scenario
- 7.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory Framework/ Reimbursement Structure
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory Framework/ Reimbursement Structure
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory Framework/ Reimbursement Structure
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory Framework/ Reimbursement Structure
- 7.5.5.3. Competitive Scenario
- 7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.6. Denmark
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory Framework/ Reimbursement Structure
- 7.5.6.3. Competitive Scenario
- 7.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Regulatory Framework/ Reimbursement Structure
- 7.5.7.3. Competitive Scenario
- 7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.8. Norway
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Regulatory Framework/ Reimbursement Structure
- 7.5.8.3. Competitive Scenario
- 7.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key Country Dynamics
- 7.6.1.2. Regulatory Framework/ Reimbursement Structure
- 7.6.1.3. Competitive Scenario
- 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory Framework/ Reimbursement Structure
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory Framework/ Reimbursement Structure
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory Framework/ Reimbursement Structure
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.5. Thailand
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory Framework/ Reimbursement Structure
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory Framework/ Reimbursement Structure
- 7.6.6.3. Competitive Scenario
- 7.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory Framework/ Reimbursement Structure
- 7.7.2.3. Competitive Scenario
- 7.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Regulatory Framework/ Reimbursement Structure
- 7.7.3.3. Competitive Scenario
- 7.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory Framework/ Reimbursement Structure
- 7.8.2.3. Competitive Scenario
- 7.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory Framework/ Reimbursement Structure
- 7.8.3.3. Competitive Scenario
- 7.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Regulatory Framework/ Reimbursement Structure
- 7.8.4.3. Competitive Scenario
- 7.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Regulatory Framework/ Reimbursement Structure
- 7.8.5.3. Competitive Scenario
- 7.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/ Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key Company Heat Map Analysis, 2024
- 8.4. Company Profiles
- 8.4.1. Puritan Medical Products
- 8.4.1.1. Company Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Copan Diagnostics Inc.
- 8.4.2.1. Company Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. BD (Becton, Dickinson and Company)
- 8.4.3.1. Company Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Thermo Fisher Scientific Inc.
- 8.4.4.1. Company Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. QuidelOrtho Corporation
- 8.4.5.1. Company Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. Longhorn Vaccines and Diagnostics, LLC
- 8.4.6.1. Company Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Pretium Packaging
- 8.4.7.1. Company Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Trinity Biotech
- 8.4.8.1. Company Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Medical Wire & Equipment
- 8.4.9.1. Company Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. HiMedia Laboratories, LLC
- 8.4.10.1. Company Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
- 8.4.11. Hardy Diagnostics
- 8.4.11.1. Company Overview
- 8.4.11.2. Financial Performance
- 8.4.11.3. Product Benchmarking
- 8.4.11.4. Strategic Initiatives
- 8.4.12. Wuxi NEST Biotechnology Co., Ltd. (Nest Scientific)
- 8.4.12.1. Company Overview
- 8.4.12.2. Financial Performance
- 8.4.12.3. Product Benchmarking
- 8.4.12.4. Strategic Initiatives
- 8.4.13. VIRCELL SL
- 8.4.13.1. Company Overview
- 8.4.13.2. Financial Performance
- 8.4.13.3. Product Benchmarking
- 8.4.13.4. Strategic Initiatives
- 8.4.14. DiaSorin S.p.A.
- 8.4.14.1. Company Overview
- 8.4.14.2. Financial Performance
- 8.4.14.3. Product Benchmarking
- 8.4.14.4. Strategic Initiatives
- 8.4.15. Titan Biotech
- 8.4.15.1. Company Overview
- 8.4.15.2. Financial Performance
- 8.4.15.3. Product Benchmarking
- 8.4.15.4. Strategic Initiatives